{"url":"https://nivawealth.com/firms/royalty-pharma-sub-manager-335070","iapdUrl":"https://adviserinfo.sec.gov/firm/summary/335070","regulatoryAum":19638739455,"crd":"335070","secFileNumber":"801-132133","legalName":"Royalty Pharma Sub-Manager, LLC","displayName":"Royalty Pharma Sub-Manager","website":"https://royaltypharma.com","founded":null,"organization":"Delaware limited liability company","fiscalYearEnd":"December","headquarters":{"street":"110 East 59th Street","city":"New York","state":"NY","stateName":"New York","country":"United States","postalCode":"10022"},"tradeNames":[],"registration":{"secApproved":"7 March 2025","noticeFilings":null,"latestNoticeFiling":null},"staff":{"employees":91,"advisory":48,"brokerDealerReps":0,"insuranceAgents":0,"promoters":0},"aum":{"discretionary":19638739455,"discretionaryAccounts":7,"nonDiscretionary":0,"nonDiscretionaryAccounts":0,"wrapProgram":null,"nonUsClientsPct":86,"nonAumClients":0},"clientTypes":[{"label":"Pooled investment vehicles","clients":7,"regulatoryAum":19638739455}],"fees":[],"feeNotes":[],"feePrograms":[],"brochureCoverage":{"scope":"known_documents","status":"not_processed","checkedAt":null,"documents":[]},"custodians":[],"custodyNote":"Royalty Pharma Sub-Manager has custody of $19.63B for 5 clients.","otherCustodians":[],"leadership":[{"name":"Pablo Legorreta","title":"Chief Executive Officer","crd":"2550243"},{"name":"Terrance Coyne","title":"Executive Vice President and Chief Financial Officer","crd":"5224286"},{"name":"Arthur McGivern","title":"Executive Vice President and General Counsel","crd":"7716784"},{"name":"Carolyn Rubin","title":"Chief Compliance Officer","crd":"2829922"}],"ownership":[{"label":"Royalty Pharma Manager, LLC","detail":"Sole member in the 75% or more ownership band and a control person, since May 2025."},{"label":"Royalty Pharma Holdings LTD","detail":"Indirect owner: a owner of Royalty Pharma Manager, LLC in the 75% or more band and a control person, since May 2025.","parent":"Royalty Pharma Manager, LLC"},{"label":"Royalty Pharma PLC","detail":"Indirect owner: a owner of Royalty Pharma Holdings LTD in the 50% to 75% band, since May 2025.","parent":"Royalty Pharma Holdings LTD"}],"branchOffices":null,"filedOffices":{"otherThanPrincipal":0,"privateResidences":0},"listedOfficeAddresses":1,"officesByState":[{"state":"New York","offices":1,"addresses":[{"street":"110 East 59th Street","city":"New York","headquarters":true}]}],"advFacts":{"source":{"file":"ia100226.zip","asOf":"2 October 2026"},"telephone":"212-883-0200","stateRegisteredReps":0,"otherAdviserReps":0,"compensation":["A percentage of assets under management","Fixed fees (other than subscription fees)","Performance-based fees","Other"],"activities":["Portfolio management for pooled investment vehicles (other than investment companies)"],"financialPlanningClients":"0","assetMix":[],"privateFunds":2},"sources":{"adv1FilingDate":"4 May 2026","adv1Url":"https://reports.adviserinfo.sec.gov/reports/ADV/335070/PDF/335070.pdf","brochureDate":null,"brochureUrl":null,"iapdCompiledDate":null,"retrievedDate":"15 October 2026","retrievedOn":"2026-10-15","adv1Pages":{},"brochurePages":{}},"otherBusiness":[],"faq":[{"question":"How many clients does Royalty Pharma Sub-Manager have?","answer":"Royalty Pharma Sub-Manager has 7 clients and manages $19.6 billion for them, as of May 2026.","source":"Form ADV Part 1A, Items 5.D and 5.F, filed 4 May 2026","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What services does Royalty Pharma Sub-Manager offer?","answer":"Royalty Pharma Sub-Manager provides portfolio management for pooled vehicles.","source":"Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How many financial advisors does Royalty Pharma Sub-Manager have?","answer":"Royalty Pharma Sub-Manager has 0 investment adviser representatives registered with state securities authorities, out of 91 employees, and 48 perform investment advisory functions. None are registered representatives of a broker-dealer or licensed insurance agents.","source":"Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Who owns Royalty Pharma Sub-Manager?","answer":"Royalty Pharma Sub-Manager is owned through a chain of holding companies by Royalty Pharma PLC. Its direct owner is Royalty Pharma Manager, LLC (75% or more).","source":"Form ADV Part 1A, Schedules A and B, filed 4 May 2026","sourceRef":{"doc":"adv1","section":"scheduleA"}},{"question":"How does Royalty Pharma Sub-Manager get paid?","answer":"Royalty Pharma Sub-Manager is paid through a percentage of assets under management, fixed fees, performance-based fees and other arrangements. Its Form ADV lists no commissions among how it is paid.","source":"Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}}],"holdings":{"url":"https://nivawealth.com/firms/royalty-pharma-sub-manager-335070/holdings","form":"13F-HR","periodOfReport":"2026-06-30","filedOn":"2026-08-21","filingIndexUrl":"https://www.sec.gov/Archives/edgar/data/2081668/000208166826000018/0002081668-26-000018-index.html","totalValue":241917580,"positionCount":4,"top10Share":1,"top10":[{"issuer":"CYTOKINETICS, INC","titleOfClass":"COM","cusip":"23282W605","value":83519594,"shares":980392,"shareType":"SH","priorValue":64617637,"priorShares":980392},{"issuer":"ZENAS BIOPHARMA, INC.","titleOfClass":"COM","cusip":"98937L105","value":60611247,"shares":2388150,"shareType":"SH","priorValue":46688333,"priorShares":2388150},{"issuer":"KAILERA THERAPEUTICS","titleOfClass":"COM","cusip":"482931102","value":54091515,"shares":2455357,"shareType":"SH"},{"issuer":"BIOHAVEN LTD","titleOfClass":"COM","cusip":"G1110E107","value":43695224,"shares":2936507,"shareType":"SH","priorValue":24842849,"priorShares":2936507}],"positionsListed":4,"positions":[{"issuer":"CYTOKINETICS, INC","titleOfClass":"COM","cusip":"23282W605","value":83519594,"shares":980392,"shareType":"SH","priorValue":64617637,"priorShares":980392},{"issuer":"ZENAS BIOPHARMA, INC.","titleOfClass":"COM","cusip":"98937L105","value":60611247,"shares":2388150,"shareType":"SH","priorValue":46688333,"priorShares":2388150},{"issuer":"KAILERA THERAPEUTICS","titleOfClass":"COM","cusip":"482931102","value":54091515,"shares":2455357,"shareType":"SH"},{"issuer":"BIOHAVEN LTD","titleOfClass":"COM","cusip":"G1110E107","value":43695224,"shares":2936507,"shareType":"SH","priorValue":24842849,"priorShares":2936507}]},"notice":"Compiled from public SEC Form ADV filings on the dates in `sources`. Facts as filed; not a rating, ranking, or recommendation. Niva Wealth is not affiliated with this firm. Disciplinary history is deliberately not included here or on the page; the SEC publishes the complete record at the `iapdUrl` above."}